MA40993A - Dérivés de 4-oxo-3,4-dihydro-1,2,3-benzotriazine comme modulateurs gpr139 - Google Patents

Dérivés de 4-oxo-3,4-dihydro-1,2,3-benzotriazine comme modulateurs gpr139

Info

Publication number
MA40993A
MA40993A MA040993A MA40993A MA40993A MA 40993 A MA40993 A MA 40993A MA 040993 A MA040993 A MA 040993A MA 40993 A MA40993 A MA 40993A MA 40993 A MA40993 A MA 40993A
Authority
MA
Morocco
Prior art keywords
gpr139
modulators
dihydro
oxo
compounds
Prior art date
Application number
MA040993A
Other languages
English (en)
Other versions
MA40993B1 (fr
Inventor
Stephen Hitchcock
Betty Lam
Holger Monenschein
Holly Reichard
Original Assignee
Takeda Pharmaceuticals Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceuticals Co filed Critical Takeda Pharmaceuticals Co
Publication of MA40993A publication Critical patent/MA40993A/fr
Publication of MA40993B1 publication Critical patent/MA40993B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D253/00—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
    • C07D253/08—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 condensed with carbocyclic rings or ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/08—Radicals containing only hydrogen and carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Anesthesiology (AREA)
  • Obesity (AREA)
  • Addiction (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

La présente invention concerne un procédé permettant de traiter une maladie, un trouble ou un état pathologique associé à gpr139 à l'aide de composés de formule 1, lesquels composés sont des agonistes de gpr139, certains composés représentés par la formule 1, des compositions pharmaceutiques de ceux-ci, des procédés de fabrication desdits composés, et des intermédiaires de ceux-ci.
MA40993A 2014-11-20 2015-11-19 Dérivés de 4-oxo-3,4-dihydro-1,2,3-benzotriazine comme modulateurs gpr139 MA40993B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462082539P 2014-11-20 2014-11-20
US201562184729P 2015-06-25 2015-06-25
PCT/US2015/061607 WO2016081736A1 (fr) 2014-11-20 2015-11-19 4-oxo-3,4-dihydro-1,2,3-benzotriazines utilisées en tant que modulateurs de gpr139

Publications (2)

Publication Number Publication Date
MA40993A true MA40993A (fr) 2017-09-27
MA40993B1 MA40993B1 (fr) 2019-07-31

Family

ID=55022667

Family Applications (1)

Application Number Title Priority Date Filing Date
MA40993A MA40993B1 (fr) 2014-11-20 2015-11-19 Dérivés de 4-oxo-3,4-dihydro-1,2,3-benzotriazine comme modulateurs gpr139

Country Status (40)

Country Link
US (5) US9556130B2 (fr)
EP (2) EP3221298B1 (fr)
JP (2) JP6637501B2 (fr)
KR (1) KR102582021B1 (fr)
CN (2) CN107108531B (fr)
AU (1) AU2015349866B2 (fr)
BR (1) BR112017010311A2 (fr)
CA (1) CA2968242C (fr)
CL (1) CL2017001292A1 (fr)
CO (1) CO2017005959A2 (fr)
CR (1) CR20170275A (fr)
CY (2) CY1122613T1 (fr)
DK (2) DK3221298T3 (fr)
DO (1) DOP2017000120A (fr)
EA (1) EA033728B1 (fr)
EC (1) ECSP17038999A (fr)
ES (2) ES2897545T3 (fr)
GE (1) GEP20196961B (fr)
HR (2) HRP20212009T1 (fr)
HU (2) HUE044145T2 (fr)
IL (1) IL252311B (fr)
JO (1) JO3719B1 (fr)
LT (2) LT3536324T (fr)
MA (1) MA40993B1 (fr)
MD (1) MD3221298T2 (fr)
MX (1) MX2017006448A (fr)
MY (1) MY187423A (fr)
NZ (1) NZ732208A (fr)
PE (1) PE20170899A1 (fr)
PH (1) PH12017500920A1 (fr)
PL (2) PL3536324T3 (fr)
PT (2) PT3221298T (fr)
RS (2) RS62563B1 (fr)
SG (1) SG11201704002UA (fr)
SI (2) SI3536324T1 (fr)
TN (1) TN2017000196A1 (fr)
TW (1) TWI684590B (fr)
UA (1) UA120375C2 (fr)
UY (1) UY36406A (fr)
WO (1) WO2016081736A1 (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3719B1 (ar) 2014-11-20 2021-01-31 Takeda Pharmaceuticals Co 4- أوكسو-4،3- داي هيدرو-3،2،1- بنزوترايازينات كمواد ضابطة لأجل gpr139
US12042496B2 (en) 2018-10-16 2024-07-23 The University Of Florida Research Foundation, Incorporated Methods related to opioid therapeutics
WO2020097609A1 (fr) 2018-11-09 2020-05-14 Blackthorn Therapeutics, Inc. Modulateurs du récepteur gpr139
CN114728975A (zh) 2019-09-16 2022-07-08 武田药品工业株式会社 唑稠合的哒嗪-3(2h)-酮衍生物
WO2021127459A1 (fr) * 2019-12-20 2021-06-24 Blackthorn Therapeutics, Inc. Modulateurs du récepteur gpr139
CA3177117A1 (fr) * 2020-05-08 2021-11-11 Amin Mohamed Kamel Metabolites de benzotriazinone substitues d'un agoniste gpr139
JP2023541485A (ja) 2020-09-21 2023-10-02 武田薬品工業株式会社 統合失調症のための処置
US11760788B2 (en) 2021-03-02 2023-09-19 Pathways Neuro Pharma, Inc. Neuroreceptor compositions and methods of use
CN116693545A (zh) * 2022-03-01 2023-09-05 上海科技大学 噻吩并含氮杂环类化合物、含其的药物组合物、其制备方法及其应用
CN116693536A (zh) * 2022-03-01 2023-09-05 上海科技大学 吡咯并三嗪酮类化合物、含其的药物组合物、其制备方法及其应用
CN117986183A (zh) * 2022-10-28 2024-05-07 浙江友宁生物医药科技有限公司 一种gpr139受体激动剂、其制备方法及其应用
WO2024102802A1 (fr) * 2022-11-11 2024-05-16 Takeda Pharmaceutical Company Limited Zélatriazine pour le traitement de la dépression

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3794726A (en) * 1972-08-21 1974-02-26 Uniroyal Inc Inhibiting aggressive behavior with 1,2,3-benzotriazin-(3h)-one
US4959368A (en) 1986-02-24 1990-09-25 Mitsui Petrochemical Industries Ltd. Therapeutic agent for neurological diseases
EP0315390B1 (fr) * 1987-11-04 1994-07-20 Beecham Group Plc Composés nouveaux de 4-oxobenzotriazine et 4-oxoquinazoline
US7582766B2 (en) 2003-06-09 2009-09-01 Boehringer Ingelheim International Gmbh Inhibitors of papilloma virus
AU2004261283B2 (en) 2003-07-31 2008-05-01 Irm, Llc Bicyclic compounds and compositions as PDF inhibitors
FR2875805B1 (fr) 2004-09-27 2006-12-29 Genfit S A Composes derives de n-(benzyl) phenylacetamide substitues, preparation et utilisations
TW200736227A (en) 2005-12-23 2007-10-01 Astrazeneca Ab New compounds III
TWI433839B (zh) 2006-08-11 2014-04-11 Neomed Inst 新穎的苯并咪唑衍生物290
CN101641358A (zh) * 2007-03-23 2010-02-03 霍夫曼-拉罗奇有限公司 氮杂-吡啶并嘧啶酮衍生物
CA2709784A1 (fr) * 2007-12-21 2009-07-09 University Of Rochester Procede permettant de modifier la duree de vie d'organismes eucaryotes
WO2011138265A2 (fr) 2010-05-03 2011-11-10 Evotec Ag Dérivés d'indole et d'indazole utilisés comme antagonistes du récepteur de l'orexine
WO2014152917A2 (fr) 2013-03-14 2014-09-25 Janssen Pharmaceutica Nv Ligands physiologiques pour gpr139
JO3719B1 (ar) * 2014-11-20 2021-01-31 Takeda Pharmaceuticals Co 4- أوكسو-4،3- داي هيدرو-3،2،1- بنزوترايازينات كمواد ضابطة لأجل gpr139

Also Published As

Publication number Publication date
ES2734735T3 (es) 2019-12-11
EP3536324A1 (fr) 2019-09-11
PT3536324T (pt) 2021-11-10
DK3536324T3 (da) 2021-10-25
US9556130B2 (en) 2017-01-31
MD3221298T2 (ro) 2019-10-31
CY1122613T1 (el) 2021-05-05
RS62563B1 (sr) 2021-12-31
ECSP17038999A (es) 2017-10-31
RS59078B1 (sr) 2019-09-30
JO3719B1 (ar) 2021-01-31
NZ732208A (en) 2023-02-24
DK3221298T3 (da) 2019-06-24
JP6637501B2 (ja) 2020-01-29
HUE044145T2 (hu) 2019-09-30
HRP20212009T1 (hr) 2022-04-01
US20170095480A1 (en) 2017-04-06
EP3221298B1 (fr) 2019-04-03
EA201791096A1 (ru) 2017-11-30
SG11201704002UA (en) 2017-06-29
PE20170899A1 (es) 2017-07-12
US10561662B2 (en) 2020-02-18
CN107108531A (zh) 2017-08-29
IL252311A0 (en) 2017-07-31
JP2017535559A (ja) 2017-11-30
HUE057451T2 (hu) 2022-05-28
KR102582021B1 (ko) 2023-09-22
CA2968242A1 (fr) 2016-05-26
JP2020063285A (ja) 2020-04-23
ES2897545T3 (es) 2022-03-01
PT3221298T (pt) 2019-06-28
TW201625566A (zh) 2016-07-16
AU2015349866B2 (en) 2020-12-03
UY36406A (es) 2016-06-30
EP3221298A1 (fr) 2017-09-27
MA40993B1 (fr) 2019-07-31
EP3536324B1 (fr) 2021-10-06
CL2017001292A1 (es) 2018-02-16
US20200129518A1 (en) 2020-04-30
PH12017500920B1 (en) 2017-11-20
HRP20191003T1 (hr) 2019-08-23
TN2017000196A1 (en) 2018-10-19
CO2017005959A2 (es) 2017-10-20
US20170348319A1 (en) 2017-12-07
EA033728B1 (ru) 2019-11-20
CN112062730A (zh) 2020-12-11
US10159677B2 (en) 2018-12-25
PL3221298T3 (pl) 2019-10-31
BR112017010311A2 (pt) 2017-12-26
GEP20196961B (en) 2019-03-25
CR20170275A (es) 2017-10-30
LT3536324T (lt) 2021-12-10
US20190070187A1 (en) 2019-03-07
JP6918088B2 (ja) 2021-08-11
PL3536324T3 (pl) 2022-02-07
UA120375C2 (uk) 2019-11-25
US20160145218A1 (en) 2016-05-26
SI3536324T1 (sl) 2021-12-31
US11173161B2 (en) 2021-11-16
KR20170084324A (ko) 2017-07-19
US9770450B2 (en) 2017-09-26
IL252311B (en) 2020-07-30
SI3221298T1 (sl) 2019-10-30
PH12017500920A1 (en) 2017-11-20
MX2017006448A (es) 2017-09-12
MY187423A (en) 2021-09-22
DOP2017000120A (es) 2017-06-15
CN107108531B (zh) 2020-10-20
WO2016081736A1 (fr) 2016-05-26
CA2968242C (fr) 2022-11-08
TWI684590B (zh) 2020-02-11
LT3221298T (lt) 2019-08-12
AU2015349866A1 (en) 2017-06-15
CN112062730B (zh) 2023-09-29
CY1124929T1 (el) 2023-01-05

Similar Documents

Publication Publication Date Title
MA40993A (fr) Dérivés de 4-oxo-3,4-dihydro-1,2,3-benzotriazine comme modulateurs gpr139
EA201650031A1 (ru) Производные пирролидин-2,5-диона, фармацевтические композиции и способы применения в качестве ингибиторов ido1
EA201791002A1 (ru) Новые соединения, модулирующие fxr (nr1h4)
EA201692418A1 (ru) Замещенные индазольные соединения в качестве irak4 ингибиторов
EA201691514A1 (ru) Соединения
MA40302B1 (fr) Dérivés de carbazole
BR112016024936A2 (pt) moduladores de gpr40 à base de pirrolidina para tratamento de doenças como diabetes
PH12017500653A1 (en) Substituted benzothiophenyl derivatives as gpr40 agonists for the treatment of type ii diabetes
MA39335B1 (fr) Inhibiteurs mgat2 de dihydropyridinone à substitution tétrazolone
EA201791058A1 (ru) Морфолин- и 1,4-оксазепан-амиды в качестве агонистов соматостатинового рецептора подтипа 4 (sstr4)
AU2016380190A8 (en) Deuterated compounds for treating cancer and related diseases and conditions, and compositions and methods thereof
CL2020001589A1 (es) Proceso para la preparación de derivados de quinolina.
MA39171A1 (fr) Dérivés d'hydroxy formamide et leur utilisation
NZ746906A (en) Oxaborole esters and uses thereof
PE20160860A1 (es) Derivados de etinil-imidazolidin-2,4-diona como moduladores de mglur 4
CL2017000484A1 (es) Compuestos de azetidiniloxifenilpirrolidina
MA39315A1 (fr) Dérivés de pyridazine à utiliser dans la prévention ou le traitement d'un trouble ataxique
EA202190272A1 (ru) Дополнительно замещенные производные триазолохиноксалина
MA40366A (fr) Dérivés de tétrahydroquinoline à titre d'inhibiteurs des bromodomaines
EA202190271A1 (ru) Замещенные триазолохиноксалиновые производные
MA39337A1 (fr) Modulateurs de pyrazines de gpr6
EA201791643A1 (ru) Средства визуализации для пэт
MA44503B1 (fr) Composés de pyrrolotriazine en tant qu'inhibiteurs de tam
MA46307B1 (fr) Composition et procédés pour moduler l'expression du facteur b du complément
MA35887B1 (fr) Nouveaux dérivés morpholynyle utiles comme inhibiteurs de mogat-2